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Abstract Lectin-like OxLDL receptor-1 (LOX-1) was identi-
fied as the major receptor for oxidized low-density lipoprotein
(OxLDL) in aortic endothelial cells. LOX-1 is a type II
membrane protein that structurally belongs to the C-type lectin
family. Here, we found that the lectin-like domain of LOX-1 is
essential for ligand binding, but the neck domain is not. In
particular, the large loop between the third and fourth cysteine of
the lectin-like domain plays a critical role for OxLDL binding as
well as C-terminal end residues. Alanine-directed mutagenesis of
the basic amino acid residues around this region revealed that all
of the basic residues are involved in OxLDL binding. Simulta-
neous mutations of these basic residues almost abolished the
OxLDL-binding activity of LOX-1. Electrostatic interaction
between basic residues in the lectin-like domain of LOX-1 and
negatively charged OxLDL is critical for the binding activity of
LOX-1. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Oxidized low-density lipoprotein (OxLDL) is implicated in
the pathogenesis of atherosclerosis. Lectin-like OxLDL recep-
tor-1 (LOX-1) is the receptor for atherogenic OxLDL origi-
nally identi¢ed from endothelial cells in our laboratory [1].
Recent studies have demonstrated that LOX-1 is expressed
by an inducible manner not only in vascular endothelial cells,
but also in monocyte-derived macrophages and smooth
muscle cells [2^5]. The expression of LOX-1 is induced by
in£ammatory cytokines and OxLDL [6^9]. In vivo, LOX-1
expression is enhanced by some proatherogenic settings such
as hypertension and hyperlipidemia, and indeed accumulated
in atherosclerotic lesions [10^12].
LOX-1 is a type II membrane protein (inside out). The
unique C-type lectin-like structure in the extracellular region
is distinctive to other OxLDL receptors, including class A and
B scavenger receptors (SR) [1]. LOX-1 is composed of four
domains, an extracellular lectin-like domain at the C-terminal,
connecting neck domain, transmembrane domain, and a short
N-terminal cytoplasmic domain [13]. Our recent studies re-
vealed that the lectin domain is the functional domain of
LOX-1 for OxLDL binding. The conserved C-terminal resi-
dues of the lectin-like domain of LOX-1 are essential for
shaping the binding pocket for both OxLDL and a neutraliz-
ing antibody for LOX-1 [14].
LOX-1-expressing cells can recognize and phagocytose a
wide range of macromolecules including OxLDL as well as
aged/apoptotic cells, activated platelets, and bacteria [15^17].
Since almost all of the LOX-1 ligands so far identi¢ed showed
a negative charge [15,18], an ionic interaction between the
ligands and LOX-1 might occur as that of the class A SR
[19,20]. To identify the critical amino acids for OxLDL rec-
ognition, we generated deletion mutants and series of point
mutations by replacing the basic amino acid residues with
alanine. The results support that the positively charged amino
acids within the lectin-like domain cooperatively recognize
OxLDL.
2. Materials and methods
2.1. Lipoprotein preparations
Human LDL (1.019^1.063 g/ml) was isolated from the plasma of
healthy human subjects by sequential ultracentrifugation at 4‡C. Oxi-
dative modi¢cation of LDL was performed by incubating with
7.5 Wmol/l CuSO4 at 37‡C for 12 h. Oxidation was monitored by
measuring the amount of thiobarbituric acid-reactive substances, ap-
proximately 10 nmol malondialdehyde equivalent/mg protein in
OxLDL. The relative electrophoretic mobility of OxLDL to native
LDL was about 2.10. Labeling of OxLDL with 1,1P-dioctadecyl-
3,3,3P,3P-tetramethylindocarbocyanine perchlorate (DiI, Molecular
Probes) was performed as described [1,9].
2.2. Plasmid constructs and mutagenesis
2.2.1. Truncated mutations. The wild-type and deletion mutant
bovine LOX-1 cDNAs were ampli¢ed by polymerase chain reaction
(PCR) with wild-type bovine LOX-1 (BLOX-1) cDNA as the template
and subcloned into the pcDNA3.1/V5-His-TOPO vector (Invitrogen)
that resulted in frame fusion of V5 epitope at the C-terminus [14]. The
PCR primers used in this study are shown in Table 1. The overall
structures of the wild-type and mutated LOX-1 proteins are schemati-
cally depicted in Fig. 2. To generate deletion of neck domain of
BLOX-1, the lectin domain of BLOX-1 was ampli¢ed by PCR prim-
ers containing 5P EcoRV and 3P SalI sites with wild-type BLOX-1
cDNA as the template, and these sites were used to ligate into wild-
type pCDNABLOX-1-V5 that had been digested with EcoRV and
XhoI. To generate v195^225 (between the third and fourth cysteine)
mutant of BLOX-1, the fragment of 226^270 of BLOX-1 was ampli-
¢ed by PCR primers containing 5P EcoRI and 3P NotI sites with wild-
type pCDNABLOX-1-V5 plasmid as the template, and these sites
were used to ligate into wild-type pCDNABLOX-1-V5 that had
been digested with EcoRI and NotI.
2.2.2. Site-directed mutagenesis. Speci¢c amino acids within the
lectin-like domain were substituted using the QuikChange site-di-
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rected mutagenesis kit (Stratagene, La Jolla, CA, USA) with pcDNA-
BLOX-1-V5 as a template [14]. Cysteine, lysine and arginine residues
were changed to alanine with mutagenic primers as shown in Table 1.
Plasmids containing combination of mutations were constructed by
carrying out serial mutagenesis reactions. The mutated cDNAs were
sequenced completely to verify the mutations.
2.3. Transfection of mutated bovine LOX-1 cDNA into CHO cells
Wild-type CHO-K1 cells were maintained in Ham’s F-12 medium
(Gibco) with 10% fetal calf serum (FCS) as previously described [1].
In brief, 1.5U106 cells in 100-mm dishes were transfected with 20 Wg
plasmids using the Lipofectamine 2000 (Gibco). On the second day,
cells were harvested by trypsin and replated on 12-well dishes or
2-well chamber slides. 48 h after transfections, the cells are ready
for further analysis. To correct for the di¡erences in transfection
e⁄ciencies, the cells were co-transfected with pcDNA3.1/LacZ and
the LOX-1 activity was normalized with the L-galactosidase activity
as described [14].
2.4. Immunoblot analysis
Cells were lysed with 62.5 mmol/l Tris^HCl (pH 7.4), 2% SDS, and
10% glycerol, equal amounts of proteins were separated by SDS^poly-
acrylamide gel electrophoresis and transferred onto polyvinylidene
di£uoride (PVDF) membrane (Immobilon, Millipore). Membranes
were probed with the anti-LOX-1 monoclonal antibody (#5-2) as
described [14].
2.5. Immuno£uorescent staining and confocal microscopy
Binding and uptake of DiI-labeled OxLDL to LOX-1 transfected
CHO cells were determined by £uorescence microscopy. Brie£y, the
cells were incubated with 10 Wg/ml of DiI-labeled OxLDL at 37‡C for
3 h. After three washes with ice-cold phosphate-bu¡ered saline (PBS),
the cells were ¢xed with 3.8% (v/v) paraformaldehyde in PBS for
15 min. Cells were blocked with 0.1% bovine serum albumin in PBS
containing non-immune goat serum. Cells were stained with anti-V5
antibody for 60 min, and then with £uorescein isothiocyanate-conju-
gated goat anti-mouse IgG for 60 min in 10% FCS in PBS. The
coverslips were mounted in 80% glycerol supplemented with 2% tri-
ethylenediamine and cells were examined on a confocal microscope
(Fluoview, Olympus).
2.6. The binding and uptake of DiI-labeled OxLDL
Binding of DiI-OxLDL to wild-type or mutant BLOX-1 transfected
CHO-K1 cells, and mock (vector) transfected CHO-K1 cells were
measured after incubation in 12-well culture dishes at 4‡C as previ-
ously described [1]. Ligand uptake activity was determined by the
measurement of £uorescence of DiI. In brief, the transfected cells
were incubated 10 Wg/ml of DiI-labeled-OxLDL at 37‡C for 3 h. After
three washes with PBS, £uorescence microscopy was performed to
detect DiI-OxLDL internalized in cells. The cells were solubilized in
0.2 ml of lysis bu¡er for 20 min at room temperature on shaker for
protein and L-galactosidase determination. To measure the amounts
of DiI-OxLDL uptake in cells, 0.3 ml of isopropanol was added to
each well, and the plates were gently shaken on an orbital shaker for
15 min. The £uorescence of the extracted DiI was counted by a spec-
tro£uorometer (Spectro Fluor, Tecan) as described [6]. Speci¢c bind-
ing was determined by subtracting the value in the presence of a
50-fold excess of unlabeled OxLDL from the total value.
3. Results and discussion
The lectin-like domain of LOX-1 was highly conserved
among di¡erent species. In the previous studies, we have con-
¢rmed that lectin domain is the OxLDL-binding domain [14].
In the lectin domain, six cysteine residues are completely con-
served among all species of LOX-1 proteins. According to
other C-type lectin-like molecules [21,22], three disul¢de
bonds will be formed in bovine LOX-1, possibly bridge
Cys140[Cys(I)] and Cys151[Cys(II)] ; Cys168[Cys(III)] and
Cys260[Cys(VI)] ; Cys239[Cys(IV)] and Cys252[Cys(V)] [13].
Since mutation of the cysteine residues changes normal disul-
¢de bond formation, the stability of LOX-1 protein basal
structure might be a¡ected. Actually, the mutation of
Cys252 to alanine resulted in loss of OxLDL binding (Fig.
1). Therefore, in the present study all the cysteine residues
were kept intact for the following deletion or point mutations.
In the previous study, we demonstrated the speci¢c require-
ment of the nine C-terminal amino acids for the binding of
OxLDL to LOX-1 with the aid of neutralizing antibody for
LOX-1 [14]. To further characterize the structural require-
ments of LOX-1 for OxLDL binding, deletion mutants of
Table 1
Primers used for generating wild-type and mutations of BLOX-1
Construct Sequence of the 5P primer Sequence of the 3P primer













All sequences are from 5P to 3P direction. Nucleotides corresponding to restriction sites are underlined.
Fig. 1. Cysteine residues in the lectin domain are important to keep
LOX-1’s function. Point mutation in one of the conserved cysteine
residues of BLOX-1, Cys252 to alanine caused the loss of OxLDL-
binding activity.
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BLOX-1 lacking the neck domain, whole or part of the lectin-
like domain were constructed (Fig. 2).
As shown in Figs. 3 and 4, deletion of the neck domain did
not a¡ect the OxLDL binding and uptake, while deletion of
lectin-like domain abolished the binding activity. Therefore,
the neck domain of LOX-1 does not appear to have a direct
role in ligand recognition. In contrast, v195^225 lost OxLDL-
binding activity, suggesting the importance of the structure
around the deleted 31 amino acid residues in the large loop
between Cys(III) and Cys(IV) in lectin-like domain. The ami-
no acid sequence of LOX-1 has homology to NK cell recep-
tors, including CD94, NKG2D, Ly49-A etc. [1,13]. The equiv-
alent residues between Cys(III) and Cys(IV) of LOX-1 would
be exposed to the surface according to the known crystal
structure of CD94 [21,22].
It has been observed that positive electrostatic residues play
signi¢cant roles in ligand^receptor interactions for SRs
although the primary sequences are not necessarily identical
[23,24]. The lysine clusters in the collagen domain of SR-AI/II
constitute the OxLDL-binding sites [19,20]. Recently, Pearce
et al reported that OxLDL binding to CD36 was sensitive to
pH and ionic strength, indicating that electric interactions
may be critical for binding [25]. Therefore, we sought the
possibility that LOX-1 might bind OxLDL in a similar way
as other SRs via the clusters of positively charged residues.
In the lectin domain three clusters of basic amino acids (at
positions of R205/K206; R225/R232/R244; and K262/K263
for bovine LOX-1) are conserved among LOX-1 proteins of
all known species. The importance of K262/K263 has been
demonstrated in our former studies [14]. Here, we focused
on the internal positively charged residues among the deleted
residues in v195^225. A series of point mutations within this
region by substituting arginine/lysine to alanine were intro-
duced to BLOX-1.
Introduction of single point mutation to R205, K206, R225,
R232 or R244 of BLOX-1 resulted in a decrease in the bind-
ing activity at 4‡C, and more clearly in the binding and up-
take activity at 37‡C in the expressed cells, although the ex-
tents are variable (Fig. 3). Among them, mutation at R225
showed substantial e¡ect by reducing about 50% of the bind-
ing activity, indicating a strong requirement for this residue.
The e¡ect of the mutation at R205 or K206 was minor, but
showed signi¢cant e¡ect in the combination of R205 and
K206. This suggests the cooperative action of these adjoining
residues. Similarly, while the single mutation at R232 or R244
showed only minor e¡ect, the triple mutation at R225/R232/
R244 decreased the binding activity more than the double
mutation at R225/R232.
Interestingly, three or more point mutations (R225/R232/
R244A, R205/K206/R225/R232A) almost abolishing OxLDL
binding of LOX-1 further con¢rmed the essential roles of the
basic amino acids. The mutant LOX-1 receptors are still de-
tected by anti-V5 antibody at the plasma membrane as well as
the wild-type LOX-1, indicating the cell surface sorting of
LOX-1 was not a¡ected (Fig. 4). In addition, the expression
of mutant LOX-1 in correct size can be detected by Western
blotting with anti-LOX-1 monoclonal antibody (Fig. 5).
Therefore, the loss of OxLDL-binding activity in mutant
LOX-1-expressing cells should be ascribed to the impairment
of ligand^receptor interaction.
Fig. 2. Schematic illustration of BLOX-1 and its truncated and
point mutant constructs. Wild-type and deletion mutant bovine
LOX-1 were in frame fused to an epitope tag (V5) at the C-termi-
nus. CD, cytoplasmic domain; TM, transmembrane domain; Neck,
neck domain; Lectin domain, C-type lectin-like domain. The clus-
ters of conserved basic amino acids residues in the lectin domain
are indicated.
Fig. 3. OxLDL binding and uptake in CHO cells transfected with
wild-type or mutant BLOX-1. A: OxLDL binding at 4‡C.
B: OxLDL binding and uptake at 37‡C. The cells were incubated
with 10 Wg/ml of DiI-OxLDL for 3 h at 4‡C or 37‡C to examine
OxLDL binding or uptake in native and mutant LOX-1 transfected
CHO cells. The speci¢c binding was calculated by subtracting the
values in the presence of an excess amount of unlabeled OxLDL.
Data are mean þ S.E.M. from four separate experiments. In the left
side of the dashed line, the results represent wild-type and deletion
mutants, and the results of point mutations are in the right. Each
of the positions for substitution of the basic amino acids with
alanine (A) were indicated. *, represents P6 0.05 vs. wild-type;
#, indicates no speci¢c binding and uptake.
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The simplest explanation of the results is that the positively
charged residues might directly serve as binding pocket.
OxLDL exhibits strong negative charge since the lipid perox-
idation products were generated and linked to the degraded
ApoB moiety [26]. An ionic interaction between LOX-1 re-
ceptor and ligand would, therefore, occur at physiologic pH.
It is possible that LOX-1 ligands interact directly with those
of the charged residues within the lectin-like domain. The
mutations on basic amino acid residues may impair the inter-
action in the ligand-binding pocket.
Alternatively, the lectin-like domain must adopt a precise
conformation to achieve ligand binding, possibly through in-
tramolecular ionic interaction. The charged residues in the
lectin domain are critical to stabilize the delicate structure.
It is possible that mutations on the charged residues will alter
the delicate conformations of the receptor as well.
The identi¢cation of the amino acid residues that is essen-
tial for OxLDL binding will give a clue to design the antag-
onists for LOX-1.
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